| Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 8860738 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Staging in patients with newly diagnosed untreated cancer of the prostate has significant ramifications on the management of the disease. Currently measurement of the serum prostate-specific antigen (PSA) concentration and radionuclide bone scan are two important procedures in the metastatic workup of these patients. We retrospectively evaluated the efficacy of PSA as a staging marker to discriminate prostate cancer patients with bone metastases from those without bone metastases. MATERIALS AND METHODS: In a retrospective study 158 prostate cancer patients with (n = 21) and without (n = 137) bone metastases were analyzed. In all patients the initial PSA measurement as well as the radionuclide bone scan were evaluated. RESULTS: Patients with bone metastases demonstrated a median serum PSA concentration of 151 ng/ml and only 1 patient revealed a serum PSA concentration of <10 ng/ml. This resulted in a negative predictive value of 98%. In addition 67% of these patients demonstrated a serum PSA concentration of >100 ng/ml, which resulted in a positive predictive value of 74% and an overall accuracy of 92%. CONCLUSION: The serum PSA concentration seems to provide useful information with regard to the presence of bone metastasis in patients with newly diagnosed cancer of the prostate. A serum PSA value of <10 ng/ml nearly excludes bone metastases, whereas a serum PSA value of> 100 ng/ml is highly predictive of bone metastases. |
| | |
Authors:
|
J M Wolff; R Bares; P K Jung; U Buell; G Jakse |
Related Documents
:
|
20683058 - Preliminary results of tranilast treatment for patients with advanced castration-resist... 9436288 - Radical prostatectomy as treatment for prostate-specific antigen-detected stage t1c pro... 15780158 - Screening for prostate cancer: updated experience from the tyrol study. 15220358 - Technical variations in prostatic immunohistochemistry: need for standardisation and st... 17625788 - Novel hyaluronic acid (ha) coated drug carriers (hcdcs) for human breast cancer treatment. 21863088 - 1,3‑propane sultone. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Urologia internationalis Volume: 56 ISSN: 0042-1138 ISO Abbreviation: Urol. Int. Publication Date: 1996 |
Date Detail:
|
Created Date: 1997-02-19 Completed Date: 1997-02-19 Revised Date: 2006-10-30 |
Medline Journal Info:
|
Nlm Unique ID: 0417373 Medline TA: Urol Int Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 169-73 Citation Subset: IM |
Affiliation:
|
Departments of Urology, Aachen University of Technology, Aachen, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Bone Neoplasms / diagnosis*, radionuclide imaging, secondary* Humans Male Middle Aged Predictive Value of Tests Prostate-Specific Antigen / blood* Prostatic Neoplasms / immunology, pathology* ROC Curve Retrospective Studies Sensitivity and Specificity |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of ureteropelvic transitional cell carcinoma with bladder transitional cell carcinoma usi...
Next Document: Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-bas...